LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling
about
A kinase-independent role for EGF receptor in autophagy initiationLysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cellsMolecular mechanisms of cisplatin resistance in cervical cancerLAPTM4B is a PtdIns(4,5)P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation.FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway.LAPTM4B polymorphism increases susceptibility to multiple cancers in Chinese populations: a meta-analysis.USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway.A role for the ubiquitin ligase Nedd4 in membrane sorting of LAPTM4 proteins.LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma.LAPTM4B allele *2 is associated with breast cancer susceptibility and prognosis.LAPTM4B allele *2 is a marker of poor prognosis for gallbladder carcinomaRelationship Between LAPTM4B Gene Polymorphism and Susceptibility of Malignant Melanoma in Chinese Patients.cAMP responsive element binding protein-1 is a transcription factor of lysosomal-associated protein transmembrane-4 Beta in human breast cancer cellsLysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.Differential expression of lysosome-associated protein transmembrane-4 beta (LAPTM4B) in granulosa cells of ovarian follicles and in other bovine tissuesLAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients.The relationship between LAPTM4B polymorphisms and cancer risk in Chinese Han population: a meta-analysis.Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells.miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expressionChromatin states modify network motifs contributing to cell-specific functions.Relationship between LAPTM4B Gene Polymorphism and Prognosis of Patients following Tumor Resection for Colorectal and Esophageal Cancers.Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivoLAPTM4B Gene Expression and Polymorphism as Diagnostic Markers of Breast Cancer in Egyptian Patients.LAPTM4B: an oncogene in various solid tumors and its functions.Targeting a novel cancer-driving protein (LAPTM4B-35) by a small molecule (ETS) to inhibit cancer growth and metastasis.Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer.Drug resistance mediated by AEG-1/MTDH/LYRIC.ASIC1a mediates the drug resistance of human hepatocellular carcinoma via the Ca2+/PI3-kinase/AKT signaling pathway.MicroRNA31-NDRG3 regulation axes are essential for hepatocellular carcinoma survival and drug resistance.LAPTM4B facilitates late endosomal ceramide export to control cell death pathways.Lentivirus-mediated RNA Interference Targeting LAPTM4B Inhibits Human Ovarian Cancer Cell Invasion In Vitro.EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma.The role of phenethyl isothiocyanate on bladder cancer ADM resistance reversal and its molecular mechanism.Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line.Cross-cancer profiling of molecular alterations within the human autophagy interaction network.Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer.A comparative assessment of antiproliferative properties of resveratrol and ethanol leaf extract of Anogeissus leiocarpus (DC) Guill and Perr against HepG2 hepatocarcinoma cells.LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation.Roles of PI3K/AKT/PTEN Pathway as a Target for Pharmaceutical Therapy.
P2860
Q24314943-AFA1495B-BCD2-44E4-B6C5-FEE888776F14Q24606012-FABCF5B3-97FB-4D36-984A-46F52764C5A5Q26746228-BD9129B4-7DF7-4FE0-AA6F-DA3DD24CFE3CQ30360833-E9514851-D8D7-4285-BAFA-7EA81D353DEBQ31143865-E044DFE6-5223-4DF4-A8FC-B965C2D7CFACQ33617093-C9B4A9B4-8B65-405C-B6CA-D19FBFC3D20CQ33787348-E2746468-8EDF-476D-808D-709FA13DE1D9Q34077924-15143D84-F69F-4510-8923-84B002961BCAQ34235524-520955E8-D4C2-4803-BE9F-9406718AA0DCQ34416241-8B61FCD7-1A70-47E8-BBE7-2A2F540AEECCQ34416440-8C2FE6C8-6621-4431-887F-9DD8812558F2Q34478569-C44AA89E-524C-4ECD-AFB6-FA76533B2A5BQ34612174-2DE815A7-8012-4F28-9A42-A25671997368Q35092377-819D5458-B474-4411-84CF-E1727052DB75Q35293320-A0E5B2DC-70F5-4E55-A192-FD5EEF95C72BQ35304103-80E7083F-0ADF-40A6-BCF8-C5AFF2C75ACAQ35533654-8B246D30-E502-4F5B-83C3-21509FD38DC2Q35740073-7D3365AE-7BA7-44AD-A7A6-107B6D4FDF16Q35742473-EF3B469A-807B-4C3A-AE0A-60CBB3505D6BQ35847789-0563B39E-E050-4027-9B10-BBD852930EC0Q36071233-FDAB5149-52F5-4B68-B018-A45A3F5EAD95Q36282183-CE5D6718-7767-4AF3-A42D-DBE5E9935D50Q37041338-485C8E86-2EB8-4783-9958-D68DB89C62B8Q37510652-83A08352-6381-48F6-B665-9B65F8480C4DQ37629059-19EF7784-AB55-40F4-9F45-ADB19EB77D93Q37696458-89E6E7F1-B703-429C-8C15-1BF9D543D397Q38124429-F05A4C3A-DB97-4C7C-9F34-DCFFB80CBD87Q38727575-14B89BED-62B7-4D75-B273-6E487A94394EQ38749275-6D38080F-4F8E-47C5-A0FB-91D5DA7ABFB2Q38843156-F6671487-77B9-41B9-A22A-9735F6CCA7B8Q38845980-F1FA9CE7-ACC1-4663-ADFB-AB3EB953ED82Q38989173-5654B043-93AA-47B3-A2E6-697643D9E3DEQ39124020-140CC4E1-1995-4D33-9EA6-04B403AA9476Q39180799-B8BADC00-1534-41D2-B771-E08BFA449A84Q39535035-1D938D44-6F88-425A-9690-22E6D9BF4A75Q40698951-F33F0EC9-3E54-4BB7-89E4-409A91C1453AQ41016802-51C2635B-B41C-4679-8A22-0FD7FCC2022CQ41228283-CD5F16FF-0812-4CB5-9CB0-78BC799B389BQ41412927-5AACA9E6-9936-41B0-A692-802DA9A91835Q41958665-F4EDD435-853D-4CAF-A5A5-F4A3C6ACAE4B
P2860
LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@ast
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@en
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@en-gb
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@nl
type
label
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@ast
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@en
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@en-gb
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@nl
prefLabel
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@ast
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@en
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@en-gb
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@nl
P2093
P2860
P3181
P356
P1433
P1476
LAPTM4B: a novel cancer-associ ...... activating PI3K/AKT signaling
@en
P2093
P2860
P2888
P304
P3181
P356
10.1038/ONC.2010.303
P407
P577
2010-10-28T00:00:00Z
P5875
P6179
1017033237